KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Accumulated Expenses (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Accumulated Expenses for 8 consecutive years, with $38.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 17.61% to $38.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $38.3 million through Dec 2025, up 17.61% year-over-year, with the annual reading at $38.3 million for FY2025, 17.61% up from the prior year.
  • Accumulated Expenses hit $38.3 million in Q4 2025 for Castle Biosciences, up from $31.8 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $38.3 million in Q4 2025 to a low of $5.2 million in Q1 2021.
  • Historically, Accumulated Expenses has averaged $20.0 million across 5 years, with a median of $18.7 million in 2022.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 90.75% in 2021 and later increased 12.47% in 2024.
  • Year by year, Accumulated Expenses stood at $15.5 million in 2021, then surged by 57.32% to $24.4 million in 2022, then rose by 18.83% to $28.9 million in 2023, then rose by 12.47% to $32.6 million in 2024, then rose by 17.61% to $38.3 million in 2025.
  • Business Quant data shows Accumulated Expenses for CSTL at $38.3 million in Q4 2025, $31.8 million in Q3 2025, and $25.0 million in Q2 2025.